We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of Alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Brainstorm Cell Therapeutics Inc.는 신경퇴행성 질환 치료를 위한 자가 세포 치료제 개발 및 상업화에 주력하는 생명공학 기업입니다. 동사의 NurOwn 독점 세포 치료 플랫폼은 세포 배양법을 활용하여 자가 골수 유래 중간엽 줄기세포가 높은 수준의 신경영양인자를 분비하도록 유도하고, 신경염증 및 신경퇴행성 질환 과정을 조절하며, 신경세포 생존을 촉진하고, 신경학적 기능을 향상시킵니다. 이 회사는 근위축성 측삭 경화증(ALS) 치료를 위한 임상 3b상을 완료한 NurOwn을 개발 중이며, 진행성 다발성 경화증 치료를 위한 임상 2상, 알츠하이머병 치료, 그리고 기타 신경퇴행성 질환 치료를 위한 개발도 진행하고 있습니다. Brainstorm Cell Therapeutics Inc.는 2000년에 설립되었으며, 뉴욕주 뉴욕에 본사를 두고 있습니다.